DCT

2:26-cv-02010

BeOne Medicines USA Inc v. Zydus Pharma USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-02010, D.N.J., 02/25/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey as Defendant Zydus USA maintains its principal place of business in New Jersey, and Defendant Zydus Lifesciences, a foreign corporation, is subject to personal jurisdiction in the district. The complaint also notes that both defendants engage in patent litigation in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the cancer drug BRUKINSA® (zanubrutinib) constitutes an act of infringement of ten U.S. patents related to specific crystalline forms, formulations, and methods of use of zanubrutinib.
  • Technical Context: The technology concerns zanubrutinib, a Bruton's Tyrosine Kinase (BTK) inhibitor used to treat various B-cell cancers, and patents covering specific crystalline forms (polymorphs) and methods of using the drug to treat certain lymphomas and leukemias.
  • Key Procedural History: The litigation was initiated under the Hatch-Waxman Act following a notice letter from Zydus, dated January 19, 2026, informing Plaintiffs of its ANDA filing containing Paragraph IV certifications. These certifications allege that Plaintiffs' patents are invalid and/or will not be infringed by the proposed generic product. The complaint was filed within the statutory 45-day window.

Case Timeline

Date Event
2016-08-16 Priority Date for '117, '340, '437, '674, '500 Patents
2021-02-23 '117 Patent Issued
2023-02-28 '340 Patent Issued
2023-07-18 '357 Patent Issued
2023-10-17 '531 Patent Issued
2023-12-26 '437 Patent Issued
2024-01-30 '674 Patent Issued
2024-02-13 '596 Patent Issued
2024-02-27 '386 Patent Issued
2024-04-30 '500 Patent Issued
2025-02-25 '069 Patent Issued
2026-01-19 Zydus Sends Notice Letter to Plaintiffs
2026-02-25 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,927,117 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof", Issued 02/23/2021

The Invention Explained

  • Problem Addressed: The patent describes that the previously known form of the active compound, zanubrutinib (referred to as "Compound 1"), was amorphous and had a low glass transition temperature. ʼ117 Patent, col. 2:59-65 These characteristics can present challenges for purification, stability, and formulation into a consistent drug product. ʼ117 Patent, col. 2:63-65
  • The Patented Solution: The patent discloses a new, stable crystalline form of zanubrutinib, designated "Crystalline Form A." ʼ117 Patent, col. 3:34-36 This form is described as having a high melting point and superior physical stability under various heat and humidity conditions, making it more suitable for pharmaceutical formulation. ʼ117 Patent, col. 3:9-15 '117 Patent, col. 6:15-26 The complaint provides a chemical structure diagram of "Compound 1," which is the subject of the claimed crystalline form Compl. p. 12
  • Technical Importance: The discovery of a stable, reproducible polymorph of a drug is a critical step in pharmaceutical development, enabling the creation of a reliable oral solid dosage form with predictable bioavailability and shelf life. '117 Patent, col. 3:1-5

Key Claims at a Glance

  • The complaint asserts infringement of claims 1 through 6 of the '117 patent Compl. ¶57 Claim 1 is the lead independent claim.
  • Independent Claim 1 Elements:
    • A crystalline form of Compound 1,
    • wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°.
  • The complaint reserves the right to assert additional claims Compl. ¶57

U.S. Patent No. 11,591,340 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof", Issued 02/28/2023

The Invention Explained

  • Problem Addressed: The patent background describes the role of Bruton's tyrosine kinase (Btk) in B-cell signaling and the need for effective treatments for B-cell proliferative diseases, such as various lymphomas and leukemias. '340 Patent, col. 1:45-65
  • The Patented Solution: The patent claims a method of treating specific B-cell cancers, such as mantle cell lymphoma, by administering the specific crystalline form of zanubrutinib characterized by its distinct X-ray powder diffraction (XRPD) pattern. '340 Patent, abstract '340 Patent, col. 3:45-53 The complaint includes a chemical structure diagram of the compound used in the claimed method Compl. p. 16
  • Technical Importance: This invention provides patent protection for the specific use of the previously patented crystalline compound to treat designated diseases, thereby securing its therapeutic market application. '340 Patent, col. 18:8-16

Key Claims at a Glance

  • The complaint asserts infringement of claims 1 through 27 of the '340 patent Compl. ¶89 Independent claims 1, 8, 14, and 21 are exemplified.
  • Independent Claim 1 Elements:
    • A method for treating mantle cell lymphoma in a subject,
    • comprising administering to the subject in need thereof a crystalline form of Compound 1,
    • wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°.
  • The complaint reserves the right to assert additional claims Compl. ¶89

Multi-Patent Capsules

U.S. Patent No. 11,851,437 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof", Issued 12/26/2023

  • Technology Synopsis: This patent claims "Crystalline Form A" of zanubrutinib, defined by a specific preparation process (crystallizing from an amorphous form) and characterized by XRPD peaks and stability under certain temperature and humidity conditions. '437 Patent, abstract '437 Patent, col. 1:56-66
  • Asserted Claims: Claims 1-29 are asserted Compl. ¶¶117-118 Independent claims 1 and 11 are exemplified.
  • Accused Features: The Zydus ANDA Product is alleged to contain the claimed Crystalline Form A of zanubrutinib Compl. ¶113 Compl. ¶115

U.S. Patent No. 11,884,674 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof", Issued 01/30/2024

  • Technology Synopsis: This patent claims a method for treating a specified list of B-cell proliferative diseases by administering zanubrutinib ("Compound 1") at a specific dose of 160 mg twice a day (BID). '674 Patent, abstract '674 Patent, claim 1
  • Asserted Claims: Claims 1-28 are asserted Compl. ¶¶144-145 Independent claim 1 is exemplified.
  • Accused Features: The use of Zydus's ANDA Product, as directed by its proposed labeling, is alleged to involve treating B-cell proliferative diseases at the claimed dosage Compl. ¶142

U.S. Patent No. 11,970,500 - "Crystalline Form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, Preparation, and Uses Thereof", Issued 04/30/2024

  • Technology Synopsis: This patent claims a method for treating a specified list of B-cell proliferative diseases by administering zanubrutinib ("Compound 1") at a specific dose of 320 mg once a day (QD). '500 Patent, abstract '500 Patent, claim 1
  • Asserted Claims: Claims 1-28 are asserted Compl. ¶¶171-172 Independent claim 1 is exemplified.
  • Accused Features: The use of Zydus's ANDA Product, as directed by its proposed labeling, is alleged to involve treating B-cell proliferative diseases at the claimed dosage Compl. ¶169

U.S. Patent No. 11,701,357 - "Treatment of B cell cancers using a combination comprising BTK inhibitors", Issued 07/18/2023

  • Technology Synopsis: This patent claims a method for delaying progression or treating a B-cell cancer by administering zanubrutinib in combination with another therapeutic agent, obinutuzumab, according to a specific dosing schedule. '357 Patent, abstract '357 Patent, claim 1
  • Asserted Claims: Claims 1-3, 5, 7, and 9-19 are asserted Compl. ¶197 Independent claim 1 is exemplified.
  • Accused Features: The use of Zydus's ANDA Product, as directed by its proposed labeling, is alleged to infringe by administering zanubrutinib in the claimed combination therapy regimen Compl. ¶196

U.S. Patent No. 11,786,531 - "Methods of treating B-cell proliferative disorder", Issued 10/17/2023

  • Technology Synopsis: This patent claims a method of treating a B-cell proliferative disorder in a patient who is also receiving a moderate CYP3A inducer, comprising administering a specific high dose (about 640 mg daily) of zanubrutinib. '531 Patent, abstract '531 Patent, claim 1
  • Asserted Claims: Claims 1-30 are asserted Compl. ¶227 Independent claims 1, 11, and 21 are exemplified.
  • Accused Features: The use of Zydus's ANDA Product, as directed by its label, is alleged to involve administering zanubrutinib at the claimed high dose in patients receiving a moderate CYP3A inducer Compl. ¶221 Compl. ¶223 Compl. ¶225

U.S. Patent No. 11,896,596 - "Methods of treating B-cell proliferative disorder", Issued 02/13/2024

  • Technology Synopsis: This patent claims a method of treating a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer (specifically listing several inducers), comprising administering zanubrutinib at a dose of about 320 mg twice a day. '596 Patent, abstract '596 Patent, claim 1
  • Asserted Claims: Claims 1-26 are asserted Compl. ¶257 Independent claims 1, 9, and 18 are exemplified.
  • Accused Features: The use of Zydus's ANDA Product, as directed by its label, is alleged to involve administering zanubrutinib at the claimed dose in patients receiving a moderate CYP3A inducer Compl. ¶251 Compl. ¶253 Compl. ¶255

U.S. Patent No. 11,911,386 - "Methods of treating B-cell proliferative disorder", Issued 02/27/2024

  • Technology Synopsis: This patent claims methods of treating a B-cell proliferative disorder in a patient characterized by being administered with a moderate CYP3A inducer, by administering a total daily dose of about 640 mg of zanubrutinib, or by administering about 320 mg twice a day after selecting for such a patient. '386 Patent, abstract '386 Patent, claim 1
  • Asserted Claims: Claims 1-30 are asserted Compl. ¶287 Independent claims 1, 11, and 21 are exemplified.
  • Accused Features: The use of Zydus's ANDA Product, as directed by its label, is alleged to involve administering zanubrutinib at the claimed doses in patients receiving a moderate CYP3A inducer Compl. ¶281 Compl. ¶283 Compl. ¶285

U.S. Patent No. 12,233,069 - "Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor", Issued 02/25/2025

  • Technology Synopsis: This patent claims an oral solid tablet formulation of zanubrutinib comprising specific excipients (lactose, glidant) in defined amounts and exhibiting a particular dissolution profile. '069 Patent, abstract '069 Patent, claim 1
  • Asserted Claims: Claims 1-23 are asserted Compl. ¶314 Independent claims 1 and 17 are exemplified.
  • Accused Features: The Zydus ANDA Product is alleged to be a solid tablet for oral administration that comprises the claimed elements of the formulation Compl. ¶311 Compl. ¶313

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is "Zydus's ANDA Product," which is identified as a generic version of BRUKINSA® (zanubrutinib) tablets, 160 mg, submitted to the FDA under ANDA No. 220921 Compl. ¶2 Compl. ¶32

Functionality and Market Context

  • The Zydus ANDA Product is a pharmaceutical tablet containing zanubrutinib as its active ingredient Compl. ¶46 The complaint alleges, upon information and belief, that the product contains a specific crystalline form of zanubrutinib Compl. ¶49 Its function is to deliver zanubrutinib for the treatment of various B-cell cancers, such as mantle cell lymphoma and others Compl. ¶31
  • The complaint alleges that Zydus seeks FDA approval to commercially manufacture and sell its ANDA Product prior to the expiration of the Patents-in-Suit Compl. ¶34 This action positions the Zydus ANDA Product as a direct generic competitor to Plaintiffs' branded BRUKINSA® tablets, which are listed in the FDA's "Orange Book" as being covered by the asserted patents Compl. ¶43

IV. Analysis of Infringement Allegations

10,927,117 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A crystalline form of Compound 1, The Zydus ANDA Product is alleged to contain a crystalline form of zanubrutinib (Compound 1). ¶49 col. 3:9-11
wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°. The complaint alleges, upon information and belief, that the zanubrutinib drug substance in Zydus's ANDA Product is covered by claims of the '117 patent. ¶47; ¶49 col. 6:36-40

11,591,340 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating mantle cell lymphoma in a subject, The complaint alleges that the proposed labeling for Zydus's ANDA Product will direct its use for treating mantle cell lymphoma. ¶79; ¶81 col. 3:45-49
comprising administering to the subject in need thereof a crystalline form of Compound 1, The Zydus ANDA Product is alleged to contain the crystalline form of zanubrutinib (Compound 1). ¶78 col. 3:9-11
wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°. The crystalline form of zanubrutinib in Zydus's ANDA Product is alleged to exhibit this specific XRPD pattern. ¶81 col. 14:49-54

Identified Points of Contention

  • Evidentiary Questions: The complaint's allegations regarding the specific crystalline form of zanubrutinib in the Zydus ANDA Product are made "upon information and belief" Compl. ¶47 Compl. ¶49 A central point of contention for the composition claims will be a factual one: does the active pharmaceutical ingredient in Zydus's product, as manufactured under its ANDA, actually exhibit the XRPD peaks required by the claims?
  • Label-Based Infringement: For the method-of-use claims, such as those in the '340 patent, a key question will be whether the final, FDA-approved product label for Zydus's ANDA product will instruct, direct, or encourage physicians to prescribe the drug for the claimed indications (e.g., mantle cell lymphoma), which would support the allegation of induced infringement Compl. ¶79
  • Infringement vs. Validity: The complaint repeatedly states that in its Notice Letter, Zydus did not contest infringement of many claims on any basis other than alleged invalidity Compl. ¶56 Compl. ¶88 This suggests the primary legal battle may be over the validity of the patents rather than factual questions of infringement, though infringement must still be proven by the plaintiff.

V. Key Claim Terms for Construction

'117 Patent

  • The Term: "crystalline form"
  • Context and Importance: This term is the foundation of the composition of matter claims. Its construction is critical because it will define the boundaries of the patented polymorph. The dispute may turn on whether Zydus's product falls within this definition, particularly if it has minor impurities or slight variations in its crystal lattice.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification introduces the invention as simply "a crystalline form of Compound 1," suggesting the term could be read broadly to encompass any crystalline state, not just the specifically exemplified one. '117 Patent, col. 3:9-11
    • Evidence for a Narrower Interpretation: The patent defines "Crystalline Form A" with a high degree of specificity, providing exact XRPD peaks ʼ117 Patent, Table 1, a DSC curve with a specific melting point ʼ117 Patent, Fig. 2, and a TGA curve ʼ117 Patent, Fig. 3 A party could argue that "crystalline form" as claimed is implicitly limited to "Crystalline Form A" and must meet these specific physical characteristics.

'340 Patent

  • The Term: "treating"
  • Context and Importance: In a method-of-use claim, the definition of "treating" is pivotal for determining induced infringement. Practitioners may focus on whether the act of prescribing a drug for an indicated condition, as directed by a generic label, is sufficient to meet the "treating" limitation, regardless of the patient's ultimate clinical outcome.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent broadly discloses methods of "treating or preventing a disease associated with undesirable Btk activity," suggesting an expansive therapeutic purpose. '340 Patent, col. 18:1-5
    • Evidence for a Narrower Interpretation: The specification provides detailed clinical trial data showing specific outcomes, such as Overall Response Rate (ORR), in patients treated with zanubrutinib. '340 Patent, Table 18 A defendant might argue that "treating" requires an administration that leads to a demonstrable clinical benefit akin to those described, potentially raising the bar for proving infringement.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges active inducement of infringement based on the contention that Zydus's proposed product labeling will instruct physicians and patients to use the generic drug in a manner that infringes the asserted method-of-use patents Compl. ¶61 Compl. ¶93 It further alleges contributory infringement on the basis that the Zydus ANDA Product is especially made for an infringing use and is not a staple article of commerce suitable for substantial non-infringing use Compl. ¶62 Compl. ¶94
  • Willful Infringement: The complaint alleges that Zydus has acted with full knowledge of the Patents-in-Suit, citing Zydus's Notice Letter as evidence of this knowledge Compl. ¶65 Compl. ¶97 The allegations state Zydus acted "without a reasonable basis for believing that it would not be liable for infringement," which tracks the legal standard for willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

  • The Polymorph Question: A core factual question will be one of physical identity: what will discovery and expert analysis reveal about the solid-state characteristics of the zanubrutinib in Zydus's ANDA product? Can Plaintiffs prove by a preponderance of the evidence that it is the specific, claimed "Crystalline Form A," or will Defendants be able to demonstrate a structural or polymorphic difference sufficient to evade literal infringement?
  • The Labeling Question: A key issue for the method-of-use patents will be one of induced infringement: will the final, FDA-approved product label for Zydus's generic zanubrutinib contain explicit indications for the specific lymphoma and leukemia subtypes, and the specific dosing regimens (including those for co-administration with CYP3A inducers), that are recited in Plaintiffs' method claims?
  • The Validity Question: As this is a Hatch-Waxman case where the defendant's notice letter reportedly asserts invalidity Compl. ¶33, a central question for the court will be whether the claimed inventions-particularly the specific crystalline form of a known compound-are non-obvious over the prior art amorphous form and demonstrate unexpected results sufficient to withstand a validity challenge.
Loading Complaint